We report that chlamydiae, which are obligate intracellular bacterial pathogens, can inhibit interferon (IFN)-γ–inducible major histocompatibility complex (MHC) class II expression. However, the IFN-γ–induced IFN regulatory factor-1 (IRF-1) and intercellular adhesion molecule 1 (ICAM-1) expression is not affected, suggesting that chlamydia may selectively target the IFN-γ signaling pathways required for MHC class II expression. Chlamydial inhibition of MHC class II expression is correlated with degradation of upstream stimulatory factor (USF)-1, a constitutively and ubiquitously expressed transcription factor required for IFN-γ induction of class II transactivator (CIITA) but not of  IRF-1 and ICAM-1. CIITA is an obligate mediator of IFN-γ–inducible MHC class II expression. Thus, diminished CIITA expression as a result of USF-1 degradation may account for the suppression of the IFN-γ–inducible MHC class II in chlamydia-infected cells. These results reveal a novel immune evasion strategy used by the intracellular bacterial pathogen chlamydia that improves our understanding of the molecular basis of pathogenesis.

Tlymphocyte recognition of MHC–peptide complexes on target cells is essential for mounting an antigen-specific immune attack (1), which may in turn select pathogens able to evade immune recognition by suppressing MHC expression on the infected cells (2). Many intracellular pathogens have evolved various strategies for inhibiting MHC molecule expression on infected cells to avoid T lymphocyte recognition. For example, to escape CD8+ T cell recognition, a variety of viruses are found to suppress surface expression of MHC class I on the infected cells (312). To escape CD4+ T cell recognition, pathogens may need to inhibit the IFN-γ–inducible MHC class II expression. This is because IFN-γ induction is often required to upregulate MHC class II molecules on nonprofessional APCs, such as epithelial cells, that are usually the natural targets of intracellular pathogens. It has been demonstrated that IFN-γ– inducible MHC class II expression is inhibited in cells infected with various intracellular pathogens (1318), which suggests that suppression of IFN-γ–inducible MHC class II may represent an immune evasion strategy used by intracellular pathogens.

Chlamydia is an obligate intracellular bacterial pathogen (19) and the causative agent of many important human diseases (20, 21). Although specific immune responses are provoked after a chlamydial infection, persistent infection often occurs (22, 23). We have recently demonstrated that chlamydia possesses a strong antiapoptotic activity (24), which may allow chlamydiae to escape CD8+ T cell attack. However, CD4+ T cell–mediated immunity also plays very important roles in controlling many intracellular pathogen infections (25, 26). As viruses that suppress IFN-γ–inducible MHC class II expression on the infected cells can evade CD4+ T cell recognition (16), we hypothesize that chlamydia may have also evolved strategies for inhibiting IFN-γ induction of MHC class II, which may partially contribute to the persistent infection. To test this hypothesis, we evaluated the effect of chlamydial infection on IFN-γ– inducible MHC class II antigen expression. We have found that chlamydial infection can indeed suppress IFN-γ– inducible MHC class II expression by selective disruption of IFN-γ signaling pathways. We further demonstrated that a chlamydia-dependent proteasome-like activity is responsible for the chlamydial inhibitory effect. These observations reveal a novel immune evasion strategy used by the intracellular bacterial pathogen chlamydia.

Materials And Methods

Chlamydial Infection and IFN-γ Stimulation.

The following human cell lines were used: MCF-7 (a mammary epithelium line, provided by Dr. Arnold Greenberg of the Manitoba Cancer Foundation); MRC-5 (fibroblast; American Type Culture Collection [ATCC]); 2C4 (fibroblast; provided by Dr. George Stark of the Cleveland Clinic Foundation); and HeLa (cervical epithelium; ATCC). Cells were infected with Chlamydia trachomatis LGV2 strain at a multiplicity of infection (MOI)1 of  5 or as indicated and for 24 h or as indicated in individual experiments (24). Cells with or without infection were stimulated with human IFN-γ (PharMingen) at 200 U/ml or as indicated for another 10 h (for reverse transcriptase [RT]-PCR analysis) or 20–24 h (for flow cytometry and Western blot analysis).

Flow Cytometry.

Cell samples were stained with mouse anti– HLA-DRα (L243; ATCC), mouse anti–human intercellular adhesion molecule (ICAM)-1 (HA58; PharMingen), or normal mouse IgG (Zymed Labs., Inc.). Primary antibody binding was detected using goat anti–mouse IgG conjugated with FITC (Caltag Labs.) and analyzed with a FACSCalibur™ equipped with CellQuest software (Becton Dickinson). Dead cells were excluded by propidium iodine staining.

Western Blot Assay.

Western blot assay was carried out as we previously described (24). Rabbit antibodies were used to detect IFN-γR (SC-700; Santa Cruz Biotechnology), tyrosine-phosphorylated signal transducers and activators of transcription (STAT)1α (9171S; New England Biolabs, Inc.), IFN regulatory factor (IRF)-1 (SC-497), upstream stimulatory factor (USF)-1 (SC-229) and USF-2 (SC-862; all from Santa Cruz Biotechnology). Mouse antibodies were used to detect Janus tyrosine kinase (JAK)-1 (J24320; Transduction Labs.) and STAT1α (SC-464; Santa Cruz Biotechnology), HLA-DRα (DA6.147; provided by Dr. Peter Cresswell, Yale University; reference 27), and a chlamydial major outer membrane protein (MOMP; clone MC22, our unpublished data). Primary antibody binding was detected with horseradish peroxidase–conjugated goat anti–mouse IgG or –rabbit IgG, depending on the source of the primary antibodies, and visualized using an ECL kit (Amersham Corp.).

RT-PCR Assay.

Cell samples were collected for RNA extraction using the Rneasy Mini Kit from QIAGEN, Inc. 2 μg of total RNA was used for each cDNA synthesis with random primers and the 1st Strand cDNA synthesis kit from Boehringer Mannheim. Aliquots of the cDNA samples were used as a template for amplifying specific gene fragments by PCR reactions (28, 29). The primers used for amplification of DRα (18), DMα (29), invariant chain p41 (IP41) (29), and IRF-1 (18) were previously described. The other primers used in this study were: for class II transactivator (CIITA) amplification, 5′-GACACGGTGGCGCTGTGGGAGTC-3′ (forward) and 5′-GGCAGCCGTGAACTTGTTGTACTGG-3′ (reverse); for USF-1 amplification, 5′-TGGCACTGGTCAATTCTTTGTG (forward) and 5′-GTTGCTGTCATTCTTGATGAC (reverse); for STAT1 amplification, 5′-TAGAGTTGCTGAATGTCACTG-3′ (forward) and 5′-GGAGTGAAGCTCTTCAGTAAC-3′ (reverse); for indoleamine 2,3-dioxygenase (IDO) gene amplification, 5′-ATGCATCACCATGGCATA-3′ (forward) and 5′-GCTTCCCGCAGGCCAGCATCA-3′ (reverse); and for β-actin amplification, 5′-GTGGGGCGCCCCAGGCACCA-3′ (forward) and 5′-CTCCTTAATGTCACGCACGATTTC-3′ (reverse). β-actin mRNA detection was used as an internal control for the amount of cDNA synthesized. To ensure the specificity of the mRNA detection, all primers were designed to cover at least two exons, and parallel samples without RT were run as negative controls. The amplified DNA products were run on an agarose gel and visualized with ethidium bromide staining.

Results

Chlamydial Infection Inhibits IFN-γ–inducible MHC Class II Gene Expression.

To investigate whether chlamydia possesses the ability to evade the IFN-γ–induced immune recognition mechanism, we evaluated IFN-γ–inducible MHC class II antigen expression in cells with or without chlamydial infection. IFN-γ significantly upregulated HLA-DR surface expression on uninfected cells, whereas the chlamydia- infected cells displayed a minimal level of  DR, regardless of IFN-γ exposure (Fig. 1 A). However, chlamydial infection did not affect the IFN-γ–induced ICAM-1 surface expression (Fig. 1 A). These observations suggest that chlamydia selectively inhibits IFN-γ–inducible DR expression rather than preventing all IFN-γ dependent signaling or generally suppressing surface protein expression. Furthermore, the total cellular protein level of  IFN-γ–induced HLA-DRα was also significantly diminished in chlamydia-infected cells as compared with uninfected cells (Fig. 1 B), suggesting that the suppression of surface expression of  HLA-DR was not due to an alteration in intracellular trafficking. The chlamydial inhibition of IFN-γ–inducible HLA-DRα was reproduced in many other human cell lines, including HeLa, MRC-5, and 2C4 (Fig. 1 B), demonstrating that the inhibitory effect is not a cell line–specific phenomenon. To determine whether the chlamydial inhibition of HLA-DR expression occurs at the transcription or translation level, MHC class II mRNA levels were evaluated by semiquantitative RT-PCR. IFN-γ dramatically induced the expression of DRα, DMα, and Ip41 mRNA in the uninfected but not the infected cells (Fig. 1 C), suggesting that chlamydial inhibition of MHC class II occurred at the transcription level. Because the genes encoding the MHC class II presentation–related molecules DRα, DMα, and Ip41 share similar promoter structures and CIITA is a master regulator for the expression of these genes (30), we hypothesize that chlamydia may inhibit CIITA function or CIITA gene expression.

IFN-γ–inducible CIITA Expression Is Inhibited in Chlamydia-infected Cells.

Although CIITA is constitutively expressed in professional APCs, such as dendritic cells and B cells, IFN-γ stimulation is often required for the expression of CIITA in nonprofessional APCs, such as epithelial cells (31). CIITA mRNA expression was induced by IFN-γ in uninfected MCF-7 cells (Fig. 2 A). However, CIITA mRNA expression was significantly lower in chlamydia- infected and IFN-γ–treated cells (Fig. 2 A), in accord with chlamydial inhibition of MHC class II gene expression. To investigate how CIITA gene expression was inhibited, we measured mRNA levels for three transcription factors, USF-1, STAT1, and IRF-1, all of which are required for IFN-γ–inducible transcription of the CIITA gene (32). Both USF-1 and STAT1 mRNAs were constitutively expressed, and IRF-1 mRNA was induced by IFN-γ in MCF-7 cells regardless of chlamydial infection (Fig. 2 A), suggesting that chlamydial infection did not affect transcription of the genes for these nuclear factors. Because the three transcription factors are considered to be sufficient and necessary for the IFN-γ induction of CIITA (32), we evaluated the protein levels of these transcription factors as well as upstream molecules in the IFN-γ signaling pathway. We found that IFN-γR, JAK-1, and STAT1 protein levels were not altered by chlamydial infection (Fig. 2 B). Chlamydia did not affect IFN-γ–induced STAT1 tyrosine phosphorylation (Fig. 2 B). Furthermore, IFN-γ induced both IRF-1 and ICAM-1 expression in chlamydia-infected cells (Figs. 1 A and 2 B). As STAT1 is required for the expression of both IRF-1 and ICAM-1 genes (32, 33), we conclude that STAT1 is transcriptionally functional in chlamydia-infected cells. The IFN-γ–induced IRF-1 in chlamydia-infected cells may also be transcriptionally functional, as we found that IFN-γ induced expression of  IDO gene in chlamydia-infected cells (data not shown), and it is known that IRF-1 is required for IFN-γ induction of IDO (34). Therefore, the failure of the IFN-γ–inducible CIITA expression in chlamydia-infected cells is likely due to the deficiency in USF-1. We found that the USF-1 protein was not detectable in chlamydia-infected cells (Fig. 2 B), despite normal USF-1 mRNA expression (Fig. 2 A). We next determined the cause of the USF-1 protein loss.

USF-1 Is Degraded by a Proteasome-like Activity in Chlamydia-infected Cells.

Because USF-1 mRNA is expressed in chlamydia-infected cells with or without IFN-γ stimulation, the lack of USF-1 protein may be due to either the inhibition of translation of  USF-1 mRNA or the accelerated degradation of USF-1 protein. We tested the protein degradation hypothesis by using protease inhibitors. We found that the proteasome inhibitor lactacystin prevented USF-1 protein degradation in chlamydia-infected cells (Fig. 2 C). Furthermore, the lactacystin treatment also preserved the IFN-γ–inducible HLA-DR expression in chlamydia-infected cells (Fig. 2 C). These observations not only demonstrate that a proteasome-like activity is responsible for the loss of USF-1 protein in chlamydia-infected cells but also suggest that USF-1 degradation may be responsible for the chlamydial suppression of MHC class II expression.

Both USF-1 Degradation and MHC Class II Suppression in Chlamydia-infected Cells Are Dependent on Chlamydial but not Host Protein Synthesis.

To examine whether the USF-1 protein degradation in chlamydia-infected cells is dependent on chlamydial growth and protein synthesis, we first evaluated the relationship between the chlamydial infection dose and USF-1 degradation. As MOI (ratio of number of organisms versus number of host cells) increased, more chlamydial protein was produced and less USF-1 protein was detected (Fig. 3 A). This effect was selective, as USF-2 was not degraded, regardless of the infection dose (Fig. 3 A). The time course relationship between chlamydial growth and USF-1 degradation was also analyzed (Fig. 3 B). Although the STAT1 protein level was not affected by chlamydial infection at any time points examined, significant USF-1 degradation was detected 17 h after chlamydial infection, when chlamydial protein synthesis approached its maximum (Fig. 3 B). The role of chlamydial and host protein synthesis in USF-1 degradation was examined using antibiotics specifically inhibiting either prokaryotic or eukaryotic protein synthesis. We found that both rifampin (inhibiting prokaryotic transcription) and chloramphenicol (inhibiting prokaryotic translation) blocked chlamydial protein synthesis (Fig. 3 C). More importantly, these antibiotics also prevented USF-1 degradation and preserved HLA-DRα expression in chlamydia-infected cells (Fig. 3 C). However, treatment with penicillin failed to prevent USF-1 degradation and preserve HLA-DRα expression (Fig. 3 C). Penicillin only blocks chlamydial particle assembly without inhibiting chlamydial protein synthesis (35). Penicillin did not alter the constitutively expressed USF-1 protein level and IFN-γ–inducible HLA-DRα expression in uninfected cells (Fig. 3 C). Together, these observations demonstrate that chlamydial protein synthesis, but not particle assembly, is necessary for chlamydia-induced degradation of USF-1 protein and suppression of HLA-DRα expression. Finally, cycloheximide treatment did not affect the chlamydia- induced degradation of  USF-1 (Fig. 3 C). Because cycloheximide did not affect chlamydial protein synthesis but completely inhibited new protein synthesis by the host cell, for example, production of  IFN-γ–induced HLA-DRα (Fig. 3 C), we conclude that newly synthesized host proteins are not required for chlamydia-induced degradation of USF-1.

Discussion

We have demonstrated that the obligate intracellular bacterial pathogen chlamydia can inhibit IFN-γ–inducible MHC class II expression. This inhibitory effect has also been found with other intracellular pathogens, including leishmania (13), listeria (14), cowdria (15), and cytomegalovirus (1618). CD4+ T cell–mediated immunity plays an important role in host defense against various intracellular infections (3638). Recognition of the infected cells by CD4+ T cells often requires IFN-γ induction of MHC class II expression, because many pathogen-targeted cells, such as epithelial cells, are generally MHC class II–negative. Suppression of IFN-γ–inducible MHC class II expression may represent an efficient immune evasion strategy used by intracellular pathogens to escape host defenses. Thus, chlamydial inhibition of IFN-γ–inducible MHC class II may contribute to the persistent infection caused by chlamydia in humans (22).

It has been demonstrated that cytomegalovirus can prevent IFN-γ–inducible class II expression in infected cells by both IFN-β–mediated inhibition (17, 39) and disruption of IFN-γ intracellular signaling pathways (16, 18). However, mechanisms of IFN-γ–inducible MHC class II inhibition by many other intracellular pathogens are still not clear (1315). It was recently proposed that chlamydia may suppress IFN-γ–inducible MHC class II expression by stimulating host cells to release IFN-β (40). Here we show that the intracellular bacterial pathogen chlamydia has evolved a more specific mechanism for disrupting IFN-γ signaling pathways and inhibiting MHC class II expression. Chlamydia degrades USF-1, a downstream transcription factor required for IFN-γ–inducible MHC class II but not IRF-1 and ICAM-1 expression (Fig. 4). USF-1 degradation may represent an efficient means of interrupting IFN-γ– inducible MHC class II expression by chlamydia. Although the constitutively and ubiquitously expressed USF-1 is a member of the basic helix-loop-helix family consisting of multiple transcription factors, including Myc and USF-2, only USF-1 is both necessary and sufficient for binding to the E  box within the CIITA promoter IV and cooperating with STAT1 and IRF-1 for promoting transcription of CIITA (32). Therefore, the constitutively and ubiquitously expressed USF-1 may serve as a convenient and efficient target for chlamydia-induced degradation. The correlation between the degradation of USF-1 and the suppression of IFN-γ–inducible MHC class II further confirms that USF-1 plays a critical role in IFN-γ induction of  MHC class II (32). Besides its involvement in MHC class II expression, USF-1 also participates in many other cellular activities, including promoting the transcription of fatty acid synthase in response to insulin regulation (41), interfering with Ras transformation (42), and transactivating the promoter of the p53 tumor suppressor gene (43). Depletion of USF-1 may cause inhibition of host cell lipid biosynthesis and promotion of host cell survival, both of which are likely beneficial to the intracellular chlamydia organisms.

Proteolysis is an important aspect of normal cellular physiology (4446). Many viruses can take advantage of  host proteolysis for the purposes of evading host defenses (2, 47). For example, human cytomegalovirus infection can induce degradation of JAK-1, a critical upstream kinase required for IFN-γ JAK/STAT signaling pathways, to suppress IFN-γ–inducible MHC class II on the infected cells (18). Furthermore, the cytomegalovirus-induced degradation can be inhibited by the proteasome inhibitor Z-L3VS (18, 48), suggesting that cytomegalovirus may be able to manipulate host proteasome activity. Because USF-1 degradation by chlamydia is inhibitable by lactacystin and lactacystin is a potent proteasome inhibitor (48, 49), we propose that chlamydia may also produce a factor(s) for manipulating host proteasomes. Efforts to identify the chlamydial factor(s) are underway.

Acknowledgments

We thank Dr. Ronald N. Germain for helpful discussions and critically reading the manuscript and Drs. Peter Cresswell, George Stark, and Arnold Greenberg for providing useful reagents for this work.

This work was supported by the Medical Research Council (MRC) of Canada. G. Zhong is the recipient of an MRC scholarship.

Abbreviations used in this paper

     
  • CIITA

    class II transactivator

  •  
  • IDO

    indoleamine 2,3-dioxygenase

  •  
  • IRF

    interferon regulatory factor

  •  
  • JAK

    Janus tyrosine kinase

  •  
  • MOI

    multiplicity of infection

  •  
  • MOMP

    major outer membrane protein

  •  
  • RT

    reverse transcriptase

  •  
  • STAT

    signal transducers and activators of transcription

  •  
  • USF

    upstream stimulatory factor

References

References
1
Germain
RN
MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation
Cell
1994
76
287
299
[PubMed]
2
Ploegh
HL
Viral strategies of immune evasion
Science
1998
280
248
253
[PubMed]
3
Ahn
K
,
Gruhler
A
,
Galocha
B
,
Jones
TR
,
Wiertz
EJ
,
Ploegh
HL
,
Peterson
PA
,
Yang
Y
,
Fruh
K
The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP
Immunity
1997
6
613
621
[PubMed]
4
Hengel
H
,
Flohr
T
,
Hammerling
GJ
,
Koszinowski
UH
,
Momburg
F
Human cytomegalovirus inhibits peptide translocation into the endoplasmic reticulum for MHC class I assembly
J Gen Virol
1996
77
2287
2296
[PubMed]
5
Lehner
PJ
,
Karttunen
JT
,
Wilkinson
GW
,
Cresswell
P
The human cytomegalovirus US6 glycoprotein inhibits transporter associated with antigen processing-dependent peptide translocation
Proc Natl Acad Sci USA
1997
94
6904
6909
[PubMed]
6
Jones
TR
,
Sun
L
Human cytomegalovirus US2 destabilizes major histocompatibility complex class I heavy chains
J Virol
1997
71
2970
2979
[PubMed]
7
Jones
TR
,
Wiertz
EJ
,
Sun
L
,
Fish
KN
,
Nelson
JA
,
Ploegh
HL
Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains
Proc Natl Acad Sci USA
1996
93
11327
11333
[PubMed]
8
Machold
RP
,
Wiertz
EJ
,
Jones
TR
,
Ploegh
HL
The HCMV gene products US11 and US2 differ in their ability to attack allelic forms of murine major histocompatibility complex (MHC) class I heavy chains
J Exp Med
1997
185
363
366
[PubMed]
9
Schust
DJ
,
Tortorella
D
,
Seebach
J
,
Phan
C
,
Ploegh
HL
Trophoblast class I major histocompatibility complex (MHC) products are resistant to rapid degradation imposed by the human cytomegalovirus (HCMV) gene products US2 and US11
J Exp Med
1998
188
497
503
[PubMed]
10
Wiertz
EJ
,
Jones
TR
,
Sun
L
,
Bogyo
M
,
Geuze
HJ
,
Ploegh
HL
The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol
Cell
1996
84
769
779
[PubMed]
11
Hughes
EA
,
Hammond
C
,
Cresswell
P
Misfolded major histocompatibility complex class I heavy chains are translocated into the cytoplasm and degraded by the proteasome
Proc Natl Acad Sci USA
1997
94
1896
1901
[PubMed]
12
Collins
KL
,
Chen
BK
,
Kalams
SA
,
Walker
BD
,
Baltimore
D
HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes
Nature
1998
391
397
401
[PubMed]
13
Reiner
NE
,
Ng
W
,
Ma
T
,
McMaster
WR
Kinetics of gamma interferon binding and induction of major histocompatibility complex class II mRNA in Leishmania- infected macrophages
Proc Natl Acad Sci USA
1988
85
4330
4334
[PubMed]
14
Schuller
S
,
Kugler
S
,
Goebel
W
Suppression of major histocompatibility complex class I and class II gene expression in Listeria monocytogenes-infected murine macrophages
FEMS Immunol Med Microbiol
1998
20
289
299
[PubMed]
15
Vachiery
N
,
Trap
I
,
Totte
P
,
Martinez
D
,
Bensaid
A
Inhibition of MHC class I and class II cell surface expression on bovine endothelial cells upon infection with Cowdria ruminantium.
Vet Immunol Immunopathol
1998
61
37
48
[PubMed]
16
Heise
MT
,
Connick
M
,
Virgin
HWT
Murine cytomegalovirus inhibits interferon γ–induced antigen presentation to CD4 T cells by macrophages via regulation of expression of major histocompatibility complex class II–associated genes
J Exp Med
1998
187
1037
1046
[PubMed]
17
Heise
MT
,
Pollock
JL
,
O'Guin
A
,
Barkon
ML
,
Bormley
S
,
Virgin
HWT
Murine cytomegalovirus infection inhibits IFN-γ-induced MHC class II expression on macrophages: the role of type I interferon
Virology
1998
241
331
344
[PubMed]
18
Miller
DM
,
Rahill
BM
,
Boss
JM
,
Lairmore
MD
,
Durbin
JE
,
Waldman
JW
,
Sedmak
DD
Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathway
J Exp Med
1998
187
675
683
[PubMed]
19
Moulder
JW
Interaction of chlamydiae and host cells in vitro
Microbiol Rev
1991
55
143
190
[PubMed]
20
Grayston
JT
,
Kuo
CC
,
Campbell
LA
,
Wang
SP
,
Jackson
LA
Chlamydia pneumoniae and cardiovascular disease
Cardiologia
1997
42
1145
1151
[PubMed]
21
Grayston
JT
,
Wang
S
New knowledge of chlamydiae and the diseases they cause
J Infect Dis
1975
132
87
105
[PubMed]
22
Beatty
WL
,
Morrison
RP
,
Byrne
GI
Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis
Microbiol Rev
1994
58
686
699
[PubMed]
23
Holland
MJ
,
Bailey
RL
,
Conway
DJ
,
Culley
F
,
Miranpuri
G
,
Byrne
GI
,
Whittle
HC
,
Mabey
DC
T helper type-1 (Th1)/Th2 profiles of peripheral blood mononuclear cells (PBMC); responses to antigens of Chlamydia trachomatisin subjects with severe trachomatous scarring
Clin Exp Immunol
1996
105
429
435
[PubMed]
24
Fan
T
,
Lu
H
,
Hu
H
,
Shi
L
,
McClarty
GA
,
Nance
DM
,
Greenberg
AH
,
Zhong
G
Inhibition of apoptosis in chlamydia-infected cells: blockade of mitochondrial cytochrome c release and caspase activation
J Exp Med
1998
187
487
496
[PubMed]
25
Geginat
G
,
Lalic
M
,
Kretschmar
M
,
Goebel
W
,
Hof
H
,
Palm
D
,
Bubert
A
Th1 cells specific for a secreted protein of  Listeria monocytogenesare protective in vivo
J Immunol
1998
160
6046
6055
[PubMed]
26
Perry
LL
,
Feilzer
K
,
Caldwell
HD
Immunity to Chlamydia trachomatisis mediated by T helper 1 cells through IFN-γ-dependent and -independent pathways
J Immunol
1997
158
3344
3352
[PubMed]
27
Arunachalam
B
,
Pan
M
,
Cresswell
P
Intracellular formation and cell surface expression of a complex of an intact lysosomal protein and MHC class II molecules
J Immunol
1998
160
5797
5806
[PubMed]
28
Chang
CH
,
Fontes
JD
,
Peterlin
M
,
Flavell
RA
Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes
J Exp Med
1994
180
1367
1374
[PubMed]
29
Albanesi
C
,
Cavani
A
,
Girolomoni
G
Interferon-γ-stimulated human keratinocytes express the genes necessary for the production of peptide-loaded MHC class II molecules
J Invest Dermatol
1998
110
138
142
[PubMed]
30
Mach
B
,
Steimle
V
,
Martinez-Soria
E
,
Reith
W
Regulation of MHC class II genes: lessons from a disease
Annu Rev Immunol
1996
14
301
331
[PubMed]
31
Muhlethaler-Mottet
A
,
Otten
LA
,
Steimle
V
,
Mach
B
Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA
EMBO (Eur Mol Biol Organ) J
1997
16
2851
2860
[PubMed]
32
Muhlethaler-Mottet
A
,
Di Berardino
W
,
Otten
LA
,
Mach
B
Activation of the MHC class II transactivator CIITA by interferon-γ requires cooperative interaction between Stat1 and USF-1
Immunity
1998
8
157
166
[PubMed]
33
Walter
MJ
,
Look
DC
,
Tidwell
RM
,
Roswit
WT
,
Holtzman
MJ
Targeted inhibition of interferon-γ-dependent intercellular adhesion molecule-1 (ICAM-1) expression using dominant-negative Stat1
J Biol Chem
1997
272
28582
28589
[PubMed]
34
Chon
SY
,
Hassanain
HH
,
Pine
R
,
Gupta
SL
Involvement of two regulatory elements in interferon-gamma-regulated expression of human indoleamine 2,3- dioxygenase gene
J Interferon Cytokine Res
1995
15
517
526
[PubMed]
35
Barbour
AG
,
Amano
K
,
Hackstadt
T
,
Perry
L
,
Caldwell
HD
Chlamydia trachomatishas penicillin-binding proteins but not detectable muramic acid
J Bacteriol
1982
151
420
428
[PubMed]
36
Rakhmilevich
AL
Evidence for a significant role of CD4+ T cells in adoptive immunity to Listeria monocytogenesin the liver
Immunology
1994
82
249
254
[PubMed]
37
Kaufmann
SH
Immunity to intracellular bacteria
Annu Rev Immunol
1993
11
129
163
[PubMed]
38
Su
H
,
Messer
R
,
Whitmire
W
,
Fischer
E
,
Portis
JC
,
Caldwell
HD
Vaccination against chlamydial genital tract infection after immunization with dendritic cells pulsed ex vivo with nonviable Chlamydiae
J Exp Med
1998
188
809
818
[PubMed]
39
Sedmak
DD
,
Chaiwiriyakul
S
,
Knight
DA
,
Waldmann
WJ
The role of interferon β in human cytomegalovirus-mediated inhibition of HLA DR induction on endothelial cells
Arch Virol
1995
140
111
126
[PubMed]
40
Rodel
J
,
Groh
A
,
Vogelsang
H
,
Lehmann
M
,
Hartmann
M
,
Straube
E
Beta interferon is produced by Chlamydia trachomatis-infected fibroblast-like synoviocytes and inhibits gamma interferon-induced HLA-DR expression
Infect Immun
1998
66
4491
4495
[PubMed]
41
Wang
D
,
Sul
SH
Upstream  stimulatory factor binding to the E-box at −65 is required for insulin regulation of the fatty acid synthase promoter
J Biol Chem
1997
272
26367
26374
[PubMed]
42
Aperlo
C
,
Boulukos
EK
,
Pognonec
P
The basic region/helix-loop-helix/leucine repeat transcription factor USF interferes with Ras transformation
Eur J Biochem
1996
241
249
253
[PubMed]
43
Reisman
D
,
Rotter
V
The helix-loop-helix containing transcription factor USF binds to and transactivates the promoter of the p53 tumor suppressor gene
Nucleic Acids Res
1993
21
345
350
[PubMed]
44
Lupas
A
,
Flanagan
JM
,
Tamura
T
,
Baumeister
W
Self-compartmentalizing proteases
Trends Biochem Sci
1997
22
399
404
[PubMed]
45
Glas
R
,
Bogyo
M
,
McMaster
JS
,
Gaczynska
M
,
Ploegh
HL
A proteolytic system that compensates for loss of proteasome function
Nature
1998
392
618
622
[PubMed]
46
Gottesman
S
,
Maurizi
MR
,
Wickner
S
Regulatory subunits of energy-dependent proteases
Cell
1997
91
435
438
[PubMed]
47
Ploegh
HL
Destruction of proteins as a creative force
Immunol Today
1997
18
269
271
[PubMed]
48
Bogyo
M
,
Shin
S
,
McMaster
JS
,
Ploegh
HL
Substrate binding and sequence preference of the proteasome revealed by active-site-directed affinity probes
Chem Biol
1998
5
307
320
[PubMed]
49
Groll
M
,
Ditzel
L
,
Lowe
J
,
Stock
D
,
Bochtler
M
,
Bartunik
HD
,
Huber
R
Structure of 20S proteasome from yeast at 2.4 A resolution
Nature
1997
386
463
471
[PubMed]

Author notes

Address correspondence to Guangming Zhong, Dept. of Medical Microbiology, University of Manitoba, 508-730 William Ave., Winnipeg, Manitoba, Canada R3E OW3. Phone: 204-789-3835; Fax: 204-789-3926; E-mail: gmzhong@cc.umanitoba.ca